Bloomberg yesterday started the rumor-mill going that Sanofi-Aventis is on the prowl for a large biotech company, sending many biotech stocks higher on Friday (on a day in which the market is down).

The rumors make sense, as big pharma is constantly on the prowl for solid biotech companies. Let's take a look at the dynamics and which companies would be most attractive from a valuation standpoint. The three companies mentioned cited by Bloomberg as targets include Allergan (AGN), Biogen-Idec (BIIB), and Genzyme (GENZ).

The Wall Street Journal, trying to catch up with Bloomberg, has tossed in Amgen (AMGN), Gilead (GILD), and Celgene (CELG).

Let's take a closer look at all of these stocks to try to see who is the best bet. Biogen jumps out to me the most. Including the most recent quarterly results, Biogen is trading at a forward P/E of 10. It has an operating margin of 30%, return on equity of 16%, and has been growing at a 7% clip. The market cap is $13B.

Here's the whole list, taking into account forward P/E in relation to return on equity (ROE), one of my favored measures of valuation (ideally, the P/E will be lower in relation to a higher ROE).

1) Gilead (GILD): Forward P/E 9; ROE 50%; Market Cap. $31B

2) Amgen (AMGN): Forward P/E 9.5; ROE 22.5%; Market Cap. $50B

3) Biogen-Idec (BIIB): Forward P/E. 10; ROE 16%; Market Cap. $13B

4) Allergan (AGN): Forward P/E 17; ROE 16%; Market Cap. $19B

5) Celgene (CELG): Forward P/E 15; ROE 20%; Market Cap. $23B

6) Genzyme (GENZ): Forward P/E 14; ROE 2%; Market Cap. $14B

To me, Gilead clearly has the best numbers, and it also has a reputation for being a very well-run company. Genzyme doesn't look very attractive at all.

I doubt that Amgen is in play, it is very large (Bid would require $50B+) and the stock action today is pretty flat.

The market is voting for BIIB, and here is how these stocks are performing today:

SymbolLast TradeChangeVolumeIntradayRelated Info
GILD 1:31PM EDT 34.73 Up 0.59 Up 1.73% 5,307,023 Basic Chart, Message Boards, Key Statistics, more...
AMGN 1:31PM EDT 51.50 Down 0.52 Down 1.00% 2,905,368 Basic Chart, Message Boards, Key Statistics, more...
BIIB 1:31PM EDT 49.09 Up 2.36 Up 5.05% 6,376,347 Basic Chart, Message Boards, Key Statistics, more...
AGN 1:31PM EDT 61.64 Up 3.54 Up 6.09% 8,683,448 Basic Chart, Message Boards, Key Statistics, more...
CELG 1:31PM EDT 50.50 Up 0.88 Up 1.77% 2,835,820 Basic Chart, Message Boards, Key Statistics, more...
GENZ 1:31PM EDT 52.43 Up 2.57 Up 5.15% 4,948,441 Basic Chart, Message Boards, Key Statistics, more...

 Source: Yahoo Finance

Clearly the market doesn't think Amgen is in the mix, and it's voting heavily that BIIG or AGN are the targets.

After combing through this list it is clear to me that many of these stocks are undervalued and could indeed be taken out in the near-term. My best bets are Gilead and Biogen.

Big pharma buying biotech is one of the strongest ongoing trends. This is because large pharma companies have become less successful in developing new products with in-house R&D, and are increasingly turning to biotech companies to acquire new products.

This entry was posted on Friday, July 02, 2010 at 13:11 pm and is filed under Biotech.
Keywords: Mergers, Biogen, Acquisitions, Sanofi-Aventis, Gilead, Amgen, Pharma

Elance-oDesk Obtains $30,000,000 New Financing Round
  • Company: Elance-oDesk
  • Description: As the world's leading platform for online employment, Elance-oDesk helps businesses hire and manage in the cloud. For businesses looking to staff-up a team on an hourly or project basis, Elance-oDesk offers instant access to qualified professionals who work online and provides the tools to hire, view work as it progresses and pay for results.
  • Website: www.elance-odesk.com
  • Type: Venture Equity
  • Amount: $30,000,000
  • Round: Undisclosed
  • Purpose: Proceeds purposes were not disclosed.
  • Investors:

Scripted Garners $8,799,990 Series E Funding
  • Company: Scripted
  • Description: At Scripted, we hang our hat on imagination, and we believe that when it comes to grabbing the public's attention and holding it, what you say is second only to how you say it. And how you say it is where we excel.
  • Website: www.scripted.com
  • Type: Venture Equity
  • Amount: $8,799,990
  • Round: Series E
  • Purpose: Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
  • Investors:

Experiment Engine Receives $1,000,000 Seed Financing
  • Company: Experiment Engine
  • Description: Experiment Engine is an an A/B testing platform backed by a marketplace of designers and conversion rate experts who get paid when they make businesses more money.
  • Website: www.experimentengine.com
  • Type: Venture Equity
  • Amount: $1,000,000
  • Round: Seed
  • Purpose: Experiment Engine will use the funds to expand the conversation optimization platform and drive sales/marketing initiatives.
  • Investors: